Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):

	Three Months Ended March 31,
Net sales	2020			2019
MedSurg	$	774		$	766
Rhythm and Neuro	703			757
Cardiovascular	1,026			972
Total net sales of reportable segments	2,502			2,493
All other (Specialty Pharmaceuticals)	41			n/a
Consolidated net sales	$	2,543		$	2,493
	Three Months Ended March 31,
Income (loss) before income taxes	2020			2019
MedSurg	$	259		$	256
Rhythm and Neuro	99			155
Cardiovascular	199			275
Total operating income of reportable segments	556			686
All other (Specialty Pharmaceuticals)	26			n/a
Unallocated amounts:
Corporate expenses, including hedging activities	(33		)	(48		)
Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits	(202		)	63
Amortization expense	(201		)	(160		)
Operating income (loss)	146			541
Other expense, net	(124		)	(84		)
Income (loss) before income taxes	$	22		$	457
Operating income of reportable segments as a percentage of net sales of reportable segments	Three Months Ended March 31,
	2020			2019
MedSurg	33.4		%	33.4		%
Rhythm and Neuro	14.1		%	20.5		%
Cardiovascular	19.4		%	28.3		%